DOD Melanoma Translational Research Award | W81XWH 21 MRP TRA

FY21 Melanoma Research Program (MRP) Translational Research Award (TRA) - FAQs

What is the purpose of the FY21 MRP Translational Research Award (TRA)?

The TRA is intended to fund hypothesis-driven melanoma research that is already well advanced and positioned to deliver real-world impact. It supports translational, high-impact projects that address critical scientific or clinical problems in melanoma and that could meaningfully change how melanoma is treated and/or prevented if successful.

What kind of projects is this award designed to support?

This mechanism is aimed at mature projects with a strong base of prior results, clear next steps, and a credible path to clinical relevance. The emphasis is on accelerating promising findings toward clinical use rather than supporting early-stage exploratory concepts.

What does "translational" mean in the context of this opportunity?

In this opportunity, "translational" means the proposed work should logically build on existing progress and produce outcomes that can be advanced toward patient care. Reviewers are directed to focus on whether the research is clinically applicable, continuous with prior advances, and likely to move the field toward tangible benefits for melanoma patients.

How will applications be evaluated based on the information provided?

Reviewers are instructed to weigh whether the work builds logically and efficiently on existing progress, uses rigorous and robust study designs, and leads to outcomes that can be translated toward patient care or clinical relevance. Applications are expected to show a clear plan to accelerate results toward clinical use rather than generating only basic biological insights.

Is clinical applicability a major requirement for this award?

Yes. Clinical applicability and continuity are central themes. The opportunity prioritizes projects with a believable path to clinical relevance and an approach that moves an already-developed line of investigation closer to real-world melanoma impact.

Are human clinical materials important for this award?

Yes. A major priority is leveraging human clinical materials, especially clinical samples tied to clinical trials and/or established biorepositories. These resources help ensure that findings are grounded in patient biology and are more readily advanced toward clinical decision-making or therapeutic development.

Are projects required to use clinical trial samples or biorepository specimens?

The opportunity highlights these materials as a major priority, particularly samples associated with clinical trials and/or established biorepositories. The information provided indicates that such resources are strongly favored to keep the work anchored in patient biology and to support translational readiness.

Is this award focused on early exploratory research?

No. The TRA is described as supporting work that is already well advanced, with a strong foundation of prior results and clear next steps. The intent is to avoid funding early exploratory concepts and instead push mature projects toward clinical impact.

What diseases or topic areas are eligible under this award?

The focus must be melanoma. Studies involving non-melanoma skin cancers are not allowed under the FY21 MRP TRA, so proposed research needs to stay squarely within melanoma.

Are studies involving non-melanoma skin cancers allowed?

No. Studies involving non-melanoma skin cancers are explicitly not allowed under this FY21 award mechanism.

Are projects studying PD-1 combinations allowed?

No. The TRA is not intended to support studies focused on the clinical utility of PD-1 in combination with other therapeutics.

Can established melanoma cell lines be the primary experimental system?

No. The opportunity states that it is not intended for projects that rely on established melanoma cell lines as the primary experimental system.

Who is offering this grant opportunity?

The Department of Defense is offering the opportunity through the U.S. Army Medical Research Acquisition Activity (USAMRAA).

What is the funding opportunity number for this award?

The funding opportunity number is W81XWH-21-MRP-TRA.

What is the CFDA listing for this opportunity?

The CFDA listing is 12.420.

What type of funding instrument is used (grant vs. cooperative agreement)?

Funding is provided as either a grant or a cooperative agreement under the Department of Defense assistance framework.

What general funding category does this program fall under?

It is within the broader category of science, technology, and other research and development activities.

Who is eligible to apply?

Eligibility is described as unrestricted, meaning a wide range of organization types can apply, subject to any additional eligibility language in the full announcement.

How many awards were anticipated?

The opportunity anticipated making approximately four awards.

When was the opportunity posted and when did it close?

The opportunity was posted on May 7, 2021. The original closing date was August 26, 2021.

Is there an award ceiling or maximum budget listed?

The published "award ceiling" field is listed as 0. This typically indicates applicants should rely on the full solicitation for budget limits and structure rather than treating the summary field as a literal cap.

What does it mean that the "award ceiling" is listed as 0?

Based on the information provided, an award ceiling of 0 is best interpreted as a placeholder in the summary record. Applicants should look to the full solicitation for the actual budget limits, budget structure, and any cost constraints.

What is the overall "fit" for a strong application?

A strong application will present a clear translational story, demonstrate that the work is well advanced with solid prior data, use rigorous and robust study designs, and show a believable path toward clinical relevance. The program also prioritizes access to meaningful human clinical specimens (especially those connected to clinical trials and/or biorepositories) and a plan to move findings closer to tangible benefits for melanoma patients.